Ardelyx Focuses Resources on Late-Stage Programs and Reports Second Quarter 2017 Operational


At Ardelyx, we have advanced a unique, late-stage pipeline of programs, led by our first-in-class drug candidate, tenapanor, in Phase 3 development for both IBS-C and hyperphosphatemia, and RDX7675, our proprietary binder for the treatment of hyperkalemia, which is also in Phase 3 development, said Mike Raab, president and chief executive officer of Ardelyx. Based [ ] The post Ardelyx Focuses Resources on Late-Stage Programs and Reports Second Quarter 2017 Operational appeared first on STL News.
http://bit.ly/2up7p3V

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s